Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Stage

Acquired | Acquired

Valuation

$0000 

About Medican Holdings

Medican Holdings has been approved to receive a license in Malta that will enable it to import, extract, manufacture finished dose products, and distribute cannabis for medical purposes within Malta and the European Union.

Medican Holdings Headquarters Location

Malta

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Medican Holdings

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Medican Holdings is included in 1 Expert Collection, including Cannabis.

C

Cannabis

3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

Latest Medican Holdings News

Maricann to Pursue Malta Medical Cannabis License Independently

Jun 14, 2018

June 14, 2018 at 9:23 am Published by NCV Newswire Visit the Maricann Group Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors. Maricann Provides an Update on Malta TORONTO, June 14, 2018 (GLOBE NEWSWIRE) — Maricann Group Inc. (CSE:MARI) (FRANKFURT:75M) (OTCQB:MRRCF) (“Maricann” or the “Company) is providing an update to the market regarding their recently announced letter of intent to acquire a license in Malta.Following discussions with Malta Enterprise, the government entity responsible for the issuance of such licenses, the Company has submitted its own application for a license and has terminated its letter of intent to acquire Medican Holdings (“Medican”). Initially, Medican had received initial approval and Maricann received confirmation of the same. Malta Enterprise then contacted Maricann to request the Company make its own application, as their preference was to work through Maricann rather than Medican. The Company then submitted its own application to Malta Enterprise who have acknowledged receipt. Maricann anticipates the application to be reviewed within the next 30 days with a decision on the approval status. About Maricann Group Inc. Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) and will continue to pursue new opportunities in Europe.

  • What is Medican Holdings's latest funding round?

    Medican Holdings's latest funding round is Acquired.

  • Who are the investors of Medican Holdings?

    Investors of Medican Holdings include MariCann.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.